+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2020

  • ID: 5146849
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 78 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Argenx SE
  • GeNeuro SA
  • Immupharma Plc
  • Octapharma AG
  • Pfizer Inc
  • UCB SA
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H2 2020, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape.

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 1 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Argenx SE
  • GeNeuro SA
  • Immupharma Plc
  • Octapharma AG
  • Pfizer Inc
  • UCB SA
  • MORE
Introduction

Report Coverage
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
  • Argenx SE
  • GeNeuro SA
  • Immupharma Plc
  • Momenta Pharmaceuticals Inc
  • Octapharma AG
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd
  • UCB SA
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drug Profiles
  • efgartigimod alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • forigerimod acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones
Featured News & Press Releases
  • May 18, 2020: Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga (NewGam) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) presented at AAN 2020
  • Feb 19, 2019: Gliknik to receive $15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045
  • Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data
  • Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Argenx SE, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Immupharma Plc, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Momenta Pharmaceuticals Inc, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by UCB SA, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2020
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Argenx SE
  • GeNeuro SA
  • Immupharma Plc
  • Momenta Pharmaceuticals Inc
  • Octapharma AG
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd
  • UCB SA
Note: Product cover images may vary from those shown
Adroll
adroll